|
Video: What is a Stock Split?
|
|
Arcturus Therapeutics Holdings is a clinical -stage messenger RNA medicines and vaccine company focused on the development of infectious disease vaccines and other opportunities within liver and respiratory rare diseases. Co.'s initial COVID-19 vaccine candidate, ARCT-021, was designed to promote immune responses to the spike protein of the Severe Acute Respiratory Syndrome-2 virus, which is the part of the virus that allows infection to occur. The LUNAR-OTC development program addresses ornithine transcarbamylase (OTC) deficiency, a genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC. The LUNAR-CF program addresses cystic fibrosis lung disease. According to our ARCT split history records, Arcturus Therapeutics Holdings has had 1 split. | |
|
Arcturus Therapeutics Holdings (ARCT) has 1 split in our ARCT split history database. The split for ARCT took place on November 16, 2017. This was a 1 for 7 reverse split, meaning for each 7 shares of ARCT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.
When a company such as Arcturus Therapeutics Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ARCT split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arcturus Therapeutics Holdings shares, starting with a $10,000 purchase of ARCT, presented on a split-history-adjusted basis factoring in the complete ARCT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/10/2014 |
|
End date: |
10/08/2024 |
|
Start price/share: |
$42.42 |
|
End price/share: |
$22.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-47.03% |
|
Average Annual Total Return: |
-6.16% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,294.25 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/16/2017 | 1 for 7 |
|
|